Call Options

4 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$189.07 - $236.8 $775,187 - $970,880
-4,100 Reduced 34.75%
7,700 $1.49 Million
Q2 2024

Aug 14, 2024

BUY
$190.52 - $236.72 $1.35 Million - $1.68 Million
7,100 Added 151.06%
11,800 $2.74 Million
Q1 2024

May 15, 2024

BUY
$212.02 - $267.71 $169,616 - $214,167
800 Added 20.51%
4,700 $1.01 Million
Q4 2023

Feb 14, 2024

BUY
$222.59 - $267.94 $868,101 - $1.04 Million
3,900 New
3,900 $1.01 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.5B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.